MetLife

METNYSEUSD

THESIS ALERT

Email me when the MET thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$102.94
+$0.50 (+0.49%)Today 1M +4.18%
After hours$103.39+0.44%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$102.44
Prior regular-session close from the quote source.
$101.95–$103.24
Regular-session low and high so far today.
3.0M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Feb 3 projected
Projected for 2027-02-03 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$67.33–$106.72
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own MET if MetLife converts large, stable premium flows and an investment portfolio into predictable operating cash flow; disciplined underwriting and a deep distribution footprint let it return capital while GAAP earnings remain volatile from realized investment.

MET price history

Latest price$102.94Today+$0.50 (+0.49%)
MET +3.22%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • MetLife's revenue growth will continue to be driven by renewing and repricing of premiums and steady expansion in fee-based business (group and retail) so that top-line revenue does not decline year-over-year absent a contract loss or macro shock.StrengtheningMateriality: High

    Revenue rose from $66,905,000,000 (FY2023) to $70,986,000,000 (FY2024) to $77,084,000,000 (FY2025), showing recent positive top-line momentum. If top-line premium/fee momentum holds, operating leverage and investment scale support profits and capital returns; if material contract losses or pricing erosion occur, both earnings and cash generation fall quickly.

    Watch: Loss of a material group-benefits master contract or a shift of large employer relationships to competitors (distribution loss).

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Revenue rose from $66,905,000,000 (FY2023) to $70,986,000,000 (FY2024) to $77,084,000,000 (FY2025), showing recent positive top-line momentum.

    Open source ↗
  • Operating cash flow (premiums collected + investment income less policyholder benefits/expenses) will remain the primary funding source for dividends and buybacks, enabling shareholder returns without eroding solvency if markets remain broadly stable.StrengtheningMateriality: High

    Operating cash flow increased from $13,721,000,000 (FY2023) to $14,598,000,000 (FY2024) to $17,092,000,000 (FY2025), demonstrating rising cash generation. Sustained high operating cash flow allows MetLife to return capital while maintaining reserves; if cash generation falls, capital returns and the stock multiple are at risk.

    Watch: A prolonged fall in interest rates that compresses investment spreads and reduces future investment income.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Operating cash flow increased from $13,721,000,000 (FY2023) to $14,598,000,000 (FY2024) to $17,092,000,000 (FY2025), demonstrating rising cash generation.

    Open source ↗
  • GAAP net income and EPS will remain volatile because realized investment gains/losses and reserve/actuarial adjustments drive earnings swings; therefore operating_cash_flow and operating_income are better causal indicators of the economic business.StrengtheningMateriality: Medium

    Net income swung from $1,578,000,000 (FY2023) to $4,426,000,000 (FY2024) to $3,379,000,000 (FY2025) while operating_cash_flow rose steadily, showing divergence between cash performance and GAAP earnings. If investors focus on GAAP net income alone they will see noise; recognising the cash/investment drivers avoids overreacting to transitory accounting items. If realized losses or reserve adjustments become structural, however, GAAP volatility will signal true economic deterioration.

    Watch: A sequence of large realized investment losses, credit impairments, or material reserve increases that persist across quarters and reduce both GAAP and cash metrics.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Net income swung from $1,578,000,000 (FY2023) to $4,426,000,000 (FY2024) to $3,379,000,000 (FY2025) while operating_cash_flow rose steadily, showing divergence between cash.

    Open source ↗
  • MetLife's large asset base and cash liquidity provide flexibility to meet policyholder liabilities, absorb shocks and preserve ratings, which in turn protects pricing and distribution access.HoldingMateriality: Medium

    Total assets increased to $745,166,000,000 (FY2025) from $687,584,000,000 (FY2023), and cash balances grew to $22,032,000,000 (FY2025), indicating scale and liquidity. If the balance sheet remains deep and liquid, the company can ride market cycles and continue capital returns; if liquidity or capital erodes, regulatory/rating actions will force deleveraging and cut returns.

    Watch: Large mark-to-market losses or credit impairments materially reducing equity/capital and prompting rating agency downgrades.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Total assets increased to $745,166,000,000 (FY2025) from $687,584,000,000 (FY2023), and cash balances grew to $22,032,000,000 (FY2025), indicating scale and liquidity.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

MetLife's revenue growth will continue to be driven by renewing and repricing of premiums and steady expansion in fee-based business (group and retail) so that top-line revenue does not decline year-over-year absent a contract loss or macro shock. If top-line premium/fee momentum holds, operating leverage and investment scale support profits and capital returns; if material contract losses or pricing erosion occur, both earnings and cash generation fall quickly.

Operating cash flow (premiums collected + investment income less policyholder benefits/expenses) will remain the primary funding source for dividends and buybacks, enabling shareholder returns without eroding solvency if markets remain broadly stable. Sustained high operating cash flow allows MetLife to return capital while maintaining reserves; if cash generation falls, capital returns and the stock multiple are at risk.

GAAP net income and EPS will remain volatile because realized investment gains/losses and reserve/actuarial adjustments drive earnings swings; therefore operating_cash_flow and operating_income are better causal indicators of the economic business. If investors focus on GAAP net income alone they will see noise; recognising the cash/investment drivers avoids overreacting to transitory accounting items. If realized losses or reserve adjustments become structural, however, GAAP volatility will signal true economic deterioration.

MetLife's large asset base and cash liquidity provide flexibility to meet policyholder liabilities, absorb shocks and preserve ratings, which in turn protects pricing and distribution access. If the balance sheet remains deep and liquid, the company can ride market cycles and continue capital returns; if liquidity or capital erodes, regulatory/rating actions will force deleveraging and cut returns.

All standing thesis claims
Original report summary

MetLife converts large, stable premium flows and an investment portfolio into predictable operating cash flow; disciplined underwriting and a deep distribution footprint let it return capital while GAAP earnings remain volatile from realized investment.

Evidence assessed Nov 6, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Metlife

Where the evidence on Metlife stands: Holding on the latest evidence (Nov 6, 2026). Of its 4 thesis points, 3 strengthening and 1 holding.

Bull case: what the evidence supports

  • MetLife's revenue growth will continue to be driven by renewing and repricing of premiums and steady expansion in fee-based business (group and retail) so that top-line revenue does not decline year-over-year absent a contract loss or macro shock.

    sec.gov ↗

  • Operating cash flow (premiums collected + investment income less policyholder benefits/expenses) will remain the primary funding source for dividends and buybacks, enabling shareholder returns without eroding solvency if markets remain broadly stable.

    sec.gov ↗

  • GAAP net income and EPS will remain volatile because realized investment gains/losses and reserve/actuarial adjustments drive earnings swings; therefore operating_cash_flow and operating_income are better causal indicators of the economic business.

    sec.gov ↗

  • MetLife's large asset base and cash liquidity provide flexibility to meet policyholder liabilities, absorb shocks and preserve ratings, which in turn protects pricing and distribution access.

    sec.gov ↗

Bear case: what would count against it

  • Loss of a material group-benefits master contract or a shift of large employer relationships to competitors (distribution loss).

    sec.gov ↗

  • A prolonged fall in interest rates that compresses investment spreads and reduces future investment income.

    sec.gov ↗

  • A sequence of large realized investment losses, credit impairments, or material reserve increases that persist across quarters and reduce both GAAP and cash metrics.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Metlife

OptimistFi is watching Metlife. No break-condition checks are on record yet — they accumulate as new filings are checked.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Metlife filed an SEC 8-K on 2026-11-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Regulation FD disclosure.

    Metlife filed an SEC 8-K on 2026-09-24: Regulation FD disclosure. It is a dated development that tests the current thesis.

  3. Mixed
    Other material event.

    Metlife filed an SEC 8-K on 2026-08-17: Other material event. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Loss of a material group-benefits master contract or a shift of large employer relationships to competitors (distribution loss).
  • A prolonged fall in interest rates that compresses investment spreads and reduces future investment income.
  • A sequence of large realized investment losses, credit impairments, or material reserve increases that persist across quarters and reduce both GAAP and cash metrics.
  • Large mark-to-market losses or credit impairments materially reducing equity/capital and prompting rating agency downgrades.

MET news

Loading headlines…

Financial statements

MET income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

MET: quick answers

When does Metlife (MET) report earnings next?
Metlife's next results are projected for February 3, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
What is MET's short interest?
As of October 30, 2026, 10.7M MET shares were sold short, 1.71% of its shares outstanding, down 0.1% from the count before. At the stock's average daily volume that is 3.4 days to cover. FINRA publishes the count twice a month. MET short interest history
Have members of Congress traded MET?
131 trades in MET have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed MET trade
Which well-known investors own MET?
1 of the 37 well-known funds tracked here reported MET shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.2%. Fund portfolios

MET in well-known investors’ portfolios

1 of 37 funds reported MET shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.22%$52.6M−0.8%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.